Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

How EvoLV Stands Out in the Competitive World of Biotech Advisory: A Comparison with McKinsey & Company

Jul 06, 2025

Understanding the Biotech Advisory Landscape

The biotech industry is evolving rapidly, driven by technological advancements and innovative research. In this dynamic environment, specialized advisory firms play a crucial role in guiding companies through complex challenges. Among these firms, EvoLV and McKinsey & Company are prominent names, each offering unique strengths.

biotech industry

What Sets EvoLV Apart?

EvoLV is renowned for its in-depth industry expertise and agile approach. Focusing exclusively on the biotech sector, EvoLV brings a nuanced understanding of the field's intricacies. This specialization allows them to provide highly tailored advice that addresses specific client needs. Unlike broader management consultancies, EvoLV's niche focus ensures their consultants are well-versed in the latest trends and technologies shaping the biotech landscape.

Agility and Innovation

One of EvoLV's standout features is its agility. The firm excels in quickly adapting to industry changes and client requirements, offering innovative solutions that keep clients ahead of the curve. This nimbleness is essential in biotech, where scientific breakthroughs can rapidly alter market dynamics.

agile strategy

A Comparison with McKinsey & Company

McKinsey & Company is a titan in the consulting world, offering a broad range of services across various industries. While their expertise is undeniable, McKinsey's generalist approach can sometimes lack the deep sector-specific insights that niche firms like EvoLV provide. However, McKinsey's extensive resources and global reach offer advantages such as comprehensive market analysis and strategic foresight.

Resource Availability and Global Presence

McKinsey's global network and vast resources equip them with unparalleled data and analytical tools. This infrastructure supports large-scale projects and provides clients with insights drawn from a wide array of industries, which can be beneficial for biotech companies seeking cross-industry innovation.

global network

The Value of Specialized Expertise

In the competitive biotech advisory landscape, specialized expertise is invaluable. EvoLV's deep industry knowledge allows them to anticipate trends and identify opportunities that may not be immediately apparent to broader consultancies. Their focused approach ensures that clients receive guidance rooted in a profound understanding of biotech challenges and opportunities.

Client-Centric Solutions

At the heart of EvoLV’s service is a commitment to client-centric solutions. By prioritizing personalized advice and close collaboration, EvoLV builds strong partnerships with clients. This approach fosters trust and ensures that strategies are aligned with client goals, ultimately leading to more successful outcomes.

Choosing the Right Partner

For biotech companies, choosing between EvoLV and McKinsey & Company depends on their specific needs. EvoLV offers unparalleled specialization and agility, making it ideal for firms seeking deep industry insights. Conversely, McKinsey's broad expertise and resources are advantageous for companies looking for extensive data-driven strategies across multiple sectors.

business decision

Ultimately, both firms bring valuable strengths to the table. Understanding their unique offerings helps biotech companies make informed decisions about which advisory partner will best support their growth and innovation aspirations. In this competitive landscape, selecting the right advisor can be a critical factor in achieving sustainable success.